Literature DB >> 1650782

Purification of human respiratory syncytial virus: superiority of sucrose gradient over percoll, renografin, and metrizamide gradients.

A Mbiguino1, J Menezes.   

Abstract

A method was devised for producing and purifying human respiratory syncytial virus (HRSV) preparations with high titers. Previous attempts to obtain substantial amounts of purified human respiratory syncytial virus have been unsuccessful due to the extreme lability of this virus, its close association with the host cell membrane, and its tendency to aggregate during concentration procedures. We describe a comparative study of various purification media as well as a novel approach for obtaining high titers of HRSV. Virus was produced in HEp-2 cells grown on gelatin beads and concentrated either by precipitation with polyethylene glycol or by centrifugation over a sucrose cushion, the latter yielding 100% recovery. These procedures employed EDTA to disaggregate the virus and MgSO4 as a virus stabilizing agent. Attempts to purify HRSV over percoll, renografin and metrizamide gradients lead to loss of infectivity. Sucrose was found to represent the best purification medium with a yield of up to 60%.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650782     DOI: 10.1016/0166-0934(91)90154-r

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  32 in total

1.  Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.

Authors:  M H Skiadopoulos; A P Durbin; J M Tatem; S L Wu; M Paschalis; T Tao; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

2.  Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.

Authors:  T Tao; A P Durbin; S S Whitehead; F Davoodi; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 3.  Downstream processing and chromatography based analytical methods for production of vaccines, gene therapy vectors, and bacteriophages.

Authors:  Petra Kramberger; Lidija Urbas; Aleš Štrancar
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.

Authors:  Roberta L Crim; Susette A Audet; Steven A Feldman; Howard S Mostowski; Judy A Beeler
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

5.  Respiratory syncytial virus and neutrophil activation.

Authors:  E L Bataki; G S Evans; M L Everard
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

6.  Pulmonary matrix metalloproteinase-9 activity in mechanically ventilated children with respiratory syncytial virus.

Authors:  Michele Y F Kong; John P Clancy; Ning Peng; Yao Li; Tomasz J Szul; Xin Xu; Robert Oster; Wayne Sullender; Namasivayam Ambalavanan; J Edwin Blalock; Amit Gaggar
Journal:  Eur Respir J       Date:  2013-12-05       Impact factor: 16.671

7.  Inhibition of Na+ transport in lung epithelial cells by respiratory syncytial virus infection.

Authors:  Lan Chen; Weifeng Song; Ian C Davis; Kedar Shrestha; Erik Schwiebert; Wayne M Sullender; Sadis Matalon
Journal:  Am J Respir Cell Mol Biol       Date:  2008-10-23       Impact factor: 6.914

8.  Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Authors:  Richard Singleton; Nathalie Etchart; Sam Hou; Lisa Hyland
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.

Authors:  M H Skiadopoulos; S Surman; J M Tatem; M Paschalis; S L Wu; S A Udem; A P Durbin; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Respiratory syncytial virus inhibits lung epithelial Na+ channels by up-regulating inducible nitric-oxide synthase.

Authors:  Weifeng Song; Gang Liu; Charles A Bosworth; John R Walker; George A Megaw; Ahmed Lazrak; Edward Abraham; Wayne M Sullender; Sadis Matalon
Journal:  J Biol Chem       Date:  2009-01-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.